Drug Profile
Research programme: PEGylated clotting factors - Takeda/Nektar Therapeutics
Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Baxter International; Nektar Therapeutics
- Developer Nektar Therapeutics; Shire
- Class Blood coagulation factors; Recombinant proteins
- Mechanism of Action Blood coagulation factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological disorders; Haemophilia A
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 04 Nov 2017 No recent reports of development identified for preclinical development in Haematological-disorders in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Haemophilia-A in USA (Parenteral)